International Immunology, Vol 9, 1867-1874, Copyright © 1997 by Oxford University Press
B Jahn-Schmid, U Siemann, A Zenker, B Bohle, P Messner, FM Unger, UB Sleytr, O Scheiner, D Kraft and C Ebner
Modulation of allergic immune responses by using adequate adjuvants is a
promising concept for future immunotherapy of type I hypersensitivity. In
the present study, recombinant Bet v 1 (rBet v 1, the major birch pollen
allergen) was conjugated to cross-linked crystalline surface layer proteins
(SL) derived from Gram-positive eubacteria. T cell lines (TCL) and clones
(TCC) were established from peripheral blood of birch pollen-allergic
patients. TCL and TCC were induced either using rBet v 1 alone or rBet v
1/SL conjugates (rBet v 1/SL) as initial antigen stimulus. Cytokine
production after re- stimulation with rBet v 1 was investigated. TCL
initiated with rBet v 1/SL showed significantly increased IFN-gamma
production as compared to rBet v 1 -selected TCL. TCC were established from
TCL of five patients. As expected, the majority of CD4+ TCC induced by rBet
v 1 (55%) displayed a Th2-like pattern of cytokine production. However,
only 21% of Bet v 1-specific TCC isolated from TCL established with the Bet
v 1/SL revealed this phenotype. The majority of SL-specific TCC (80%)
belonged to the Th1 phenotype. In cultures of peripheral blood mononuclear
cells, both, SL and Bet v 1/SL (but not rBet v 1) stimulated the production
of high levels of IL-12, a pivotal mediator of Th1 responses. Moreover,
stimulation of rBet v 1-induced TCC with rBet v 1/SL led to an increased
IFN-gamma production. This effect could be reversed by neutralizing
anti-IL-12 mAb. Together these results indicate an adjuvant effect of SL
mediated by IL-12. Our results indicate that bacterial components, such as
SL, displaying adjuvant effects may be suitable for immunotherapeutical
vaccines for type I allergy.
ARTICLES
Bet v 1, the major birch pollen allergen, conjugated to crystalline bacterial cell surface proteins, expands allergen-specific T cells of the Th1/Th0 phenotype in vitro by induction of IL-12
Zentrum fur Ultrastrukturforschung und Ludwig Boltzmann-Institut fur Molekulare Nanotechnologie, Universitat fur Bodenkultur, Wein, Austria.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Gerstmayr, N. Ilk, I. Schabussova, B. Jahn-Schmid, E. M. Egelseer, U. B. Sleytr, C. Ebner, and B. Bohle A Novel Approach to Specific Allergy Treatment: The Recombinant Allergen-S-Layer Fusion Protein rSbsC-Bet v 1 Matures Dendritic Cells That Prime Th0/Th1 and IL-10-Producing Regulatory T Cells J. Immunol., December 1, 2007; 179(11): 7270 - 7275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bohle, A. Breitwieser, B. Zwolfer, B. Jahn-Schmid, M. Sara, U. B. Sleytr, and C. Ebner A Novel Approach to Specific Allergy Treatment: The Recombinant Fusion Protein of a Bacterial Cell Surface (S-Layer) Protein and the Major Birch Pollen Allergen Bet v 1 (rSbsC-Bet v 1) Combines Reduced Allergenicity with Immunomodulating Capacity J. Immunol., June 1, 2004; 172(11): 6642 - 6648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Breitwieser, E. M. Egelseer, D. Moll, N. Ilk, C. Hotzy, B. Bohle, C. Ebner, U. B. Sleytr, and M. Sara A recombinant bacterial cell surface (S-layer)-major birch pollen allergen-fusion protein (rSbsC/Bet v1) maintains the ability to self-assemble into regularly structured monomolecular lattices and the functionality of the allergen Protein Eng. Des. Sel., March 1, 2002; 15(3): 243 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Shedlock and D. B. Weiner DNA vaccination: antigen presentation and the induction of immunity J. Leukoc. Biol., December 1, 2000; 68(6): 793 - 806. [Abstract] [Full Text]
|
|